Parametrica Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Parametrica Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,348	Closed	-$228K	–	196
2021 Q1	$228K	Buy	+2,348	New	+$274K	0.11%	135
2020 Q4	–	Sell	-2,875	Closed	-$280K	–	206
2020 Q3	$280K	Buy	2,875 +1,051	+58%	+$131K	0.53%	60
2020 Q2	$283K	Buy	+1,824	New	+$277K	0.31%	85

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Parametrica Management's RETA Position: Q2 2021 in Review

Parametrica Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2021, closing a stake of 2,348 shares — an estimated $228K sold.

Parametrica Management first reported a position in RETA in Q2 2020 and held it in 3 quarters. The position peaked at $283K in Q2 2020. 194 funds tracked by Wall St. Rank hold RETA as of Q2 2021.

Parametrica Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2021 after selling out during the quarter.
Parametrica Management sold 2,348 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2021, an estimated $228K.
Parametrica Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2020 and held it in 3 quarters.
Parametrica Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $283K in Q2 2020.
194 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2021.

Based on Parametrica Management's 13F filing for Q2 2021, filed 13 Aug 2021.